OS Therapies details Leonite settlement and $10 million August note financing

OS Therapies Incorporated disclosed in two Form 8-K filings the resolution of its financing arrangement with Leonite Fund I, LP and a subsequent private placement of convertible notes.

Under the Leonite Settlement Agreement dated July 31, 2026, the Company agreed to pay Leonite $1,900,000 in cash and issue 500,000 shares of common stock on or before August 7, 2026, in full satisfaction of amounts outstanding under the Leonite Note and related transaction documents.¹ If the settlement did not close by the outside date, the Company was granted a five-business day cure period, absent Leonite's willful refusal to accept a proper tender.¹ If closing still had not occurred after the cure period, Leonite could terminate the settlement, reviving the original Leonite Note, warrant and other transaction documents as if the settlement had never been executed, with all of Leonite's prior rights and remedies preserved.¹

To fund the settlement payment, the Company issued a bridge convertible promissory note on August 2, 2026, in the principal amount of $2,200,000 for a purchase price of $2,190,000, which did not bear interest and matured on September 1, 2026 unless earlier converted.¹ On August 3, 2026, the Company used the bridge note proceeds to fund the Leonite settlement payment.¹

Separately, on August 10, 2026, the Company entered into a securities purchase agreement for senior secured convertible promissory notes with an aggregate subscription amount of up to $10,000,000, split into a $5,000,000 first tranche and an optional $5,000,000 second tranche.² At the initial closing, the $2,200,000 bridge note automatically converted into a new note and warrants under the new agreement.²